Ivonescimab Beats Imfinzi on Overall Survival in Biliary Tract Cancer

Summit Therapeutics (SMMT) partner Akeso just delivered the first Phase 3 win for a checkpoint combination in biliary tract cancer, and the fifth positive Phase 3 result overall for ivonescimab. In the China-only HARMONi-GI1 trial, ivonescimab plus chemotherapy beat durvalumab plus chemotherapy on overall survival in first-line advanced biliary tract cancer, meeting the primary endpoint at a pre-specified interim analysis. The trial also hit its secondary endpoints of progression-free survival and objective response rate.

The readout matters because the comparator is the global standard of care. Durvalumab (AstraZeneca’s Imfinzi) plus chemotherapy became the preferred first-line biliary regimen after the TOPAZ-1 trial, so beating it on overall survival is a genuine bar to clear. Biliary tract cancer is aggressive and hard to treat, with median survival under two years even on the best regimens. Ivonescimab is a PD-1/VEGF bispecific antibody that blocks the PD-1 immune checkpoint and traps VEGF, the protein that feeds tumor blood vessels, in a single molecule.

But investors should separate signal from catalyst. HARMONi-GI1 is a single-region trial run by Akeso in China, and Summit, which holds ex-China rights to the drug, has no US filing for biliary tract cancer. A China-only Phase 3 does not directly support a US approval, which typically requires registrational data from trials that include US sites. This readout validates the molecule’s reach beyond lung cancer, where its first four positive Phase 3 results came; it does not add near-term US revenue.

Ivonescimab has now gone five for five in Phase 3, across HARMONi, HARMONi-A, HARMONi-2, and HARMONi-6 in lung cancer plus this first gastrointestinal result. The breadth supports Summit’s thesis that one bispecific antibody can work across many solid tumors through a single mechanism. Ivonescimab is already approved in China for first-line squamous non-small cell lung cancer, and this readout gives Akeso a filing-ready dataset for the NMPA in biliary tract cancer.

Summit’s actual near-term event remains the November 14 PDUFA date for ivonescimab in EGFR-mutant NSCLC (the FDA’s deadline to decide on the drug application). The stock rose 4.95% to $13.36 on the news, and at a roughly $11 billion market cap, most of that valuation still hangs on the lung cancer decision. Summit has been expanding ivonescimab aggressively, including the HARMONi-GU1 bladder cancer trial. What to watch next: the detailed HARMONi-GI1 data at an upcoming conference, which will show the size of the survival benefit, and whether Akeso files for approval in China.

Source: Akeso press release

What It Means for the Trade

The 4.95% pop to $13.36 is about right for what this is: mechanism validation, not a revenue event. A $11 billion market cap company does not re-rate on a China-only biliary readout with no US filing attached. What the win actually does is widen the moat around the ivonescimab story ahead of the November 14 PDUFA in EGFR-mutant NSCLC — the event that genuinely moves the stock. Five positive Phase 3 readouts in five attempts is the kind of track record that keeps the bid under the shares between catalysts, because every incremental tumor type that responds makes the bispecific platform thesis harder to short.

The trade structure here matters. Summit holds ex-China rights, so Akeso will file this with China’s NMPA and capture the initial biliary revenue. Summit’s monetization path runs through its own US and EU trials, which means biliary tract cancer is a 2028-plus consideration for SMMT holders at best. Position for the November decision; treat HARMONi-GI1 as confirmation that the molecule works when it meets an active checkpoint comparator, which is a stronger signal than beating chemo alone.

Mechanism and Market Context

The comparison is more meaningful than a typical internal-comparator trial. Durvalumab plus gemcitabine and cisplatin became the global first-line standard off TOPAZ-1, so HARMONi-GI1 tested ivonescimab plus chemo against the regimen US oncologists would actually prescribe. Beating the standard of care on overall survival in biliary tract cancer — a disease where the best regimens still leave median survival under two years — is a real bar. Note the cross-trial caveat: any comparison between HARMONi-GI1’s survival numbers and TOPAZ-1’s is cross-trial, not head-to-head, and biliary trials differ on disease subtype mix, which swings outcomes substantially.

Mechanistically, biliary tract cancer is a plausible fit for a PD-1/VEGF bispecific. These tumors are heavily angiogenic and often inflamed but checkpoint-responsive, which is exactly why durvalumab worked in TOPAZ-1. Delivering both blockade and VEGF trapping in one molecule improves on the combo-drug alternative: bevacizumab plus checkpoint inhibition carries bleeding and hypertension management burden that a tuned bispecific may reduce, though that remains to be shown in the detailed data.

Risks and What Could Go Wrong

1. The survival margin could disappoint. “Met the primary endpoint at interim” tells you nothing about the hazard ratio. If the detailed presentation at the upcoming conference shows a marginal or immature OS benefit, the readout loses most of its read-through value.
2. China-only generalization risk. Chinese biliary tract cancer patients skew toward different etiologies — more liver fluke-associated cholangiocarcinoma versus Western cohorts — so regulators and oncologists will ask whether the result travels.
3. The November 14 PDUFA dwarfs everything. A CRL or delayed decision in NSCLC would hit the stock regardless of how many tumor types the China program validates.

Size this as a catalyst trade around November 14, not a platform buy on biliary news.